Working together for better blood pressure control and cardiovascular disease reduction
Hypertension is a leading global health risk and is the primary cause of premature mortality throughout the world . Worldwide, hypertension (SBP 140 mmHg or higher) is estimated to cause 106.3 annual deaths per 100 000, and loss of disability-adjusted life-years (DALYs) associated with hypertension were 7.8 million in 2015 . Understandably, lowering blood pressure (BP) in hypertensive patients is the most important and fundamental task for the clinicians [3,4]. A great number of clinical trials testing the effects of BP reduction (versus placebo or less-intense treatment) were conducted in the past 50 years and have clearly shown that antihypertensive treatment is associated with a marked reduction of fatal and nonfatal cardiovascular events [5,6]. Established in 1966, the International Society of Hypertension (ISH) is dedicated to research into the causes of hypertension and best treatment for raised BP. ISH activities have encouraged new researchers, supported policy-makers, educated students and primary physicians throughout 50 years.